URML-3881 (URML3881) is a potent, specific MEK1/2 inhibitor IC50 of 30 nM in a cell-free kinase inhibition assay.
URML-3881 shows no inhibition among a panel of other kinases including MEK 3 and MEK5, which are activated in alternative MAPK signaling pathways.
URML-3881 reduces MAPK pathway activity in clear cell ovarian cancer (CCOC).
URML-3881 causes reduced CCOC viability due to induction of tumor cell apoptosis and inhibition of proliferation.
URML-3881 abrogates cisplatin-induced prosurvival MAPK signaling in CCOC, resulting in durable and dramatic tumor regression in vivo.
